MINNEAPOLIS/NASHVILLE, Tenn., (Reuters) – Confronted with a growing meningitis scare, states are coming under enormous pressure to meet federal requests that they contact more than 1,000 hospitals and clinics that received any injectable drugs from the company at the center of the deadly outbreak.
For weeks authorities have been attempting to track down and recall the original three lots of a single steroid compound produced by the New England Compounding Center and linked to the meningitis outbreak. Those lots were shipped to 23 states and 76 facilities.
Already a challenging effort, the job was made markedly harder in recent days when the Food and Drug Administration said that “out of an abundance of caution” it had expanded the list of products shipped from the NECC that needed to be found.
The result was the FDA sent state health authorities some 131,000 shipping invoices from NECC to help them identify facilities across the nation – enough to make a paper stack more than 40 feet high. From this they hope to identify the patients.
The list of NECC products fills 70 pages. The FDA specifically advised doctors to alert patients who received injected NECC drugs during heart and eye surgeries that the company produced after May 21.
None of the additional drugs covered by the FDA request have b een linked to the outbreak, which as of Thursday had led to 20 deaths among the 254 people sickened with meningitis and three identified with peripheral infections to joints.
One example of the monumental task is Pennsylvania. Only two facilities in the state received recalled suspect steroid medication linked to the meningitis outbreak and the state has so far identified one patient stricken with the disease.
